Kit for activating sarcoma specific immunity response

An immune response and kit technology, applied in the field of kits for enhancing anti-cancer immunity

Inactive Publication Date: 2016-01-06
SHANGHAI LONGYAO BIOTECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, DC1 cells highly expressing IL12 loaded with tumor-specific antigen peptides can provide a strategy for enhancing the efficacy of antigen peptide-b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for activating sarcoma specific immunity response
  • Kit for activating sarcoma specific immunity response
  • Kit for activating sarcoma specific immunity response

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1 (cell culture supernatant is T cell culture supernatant)

[0034] When the kit of the present invention is used to activate the specific immune response of sarcoma patients, the preparation of type 1 polarized dendritic cells (type1 polarized dendritic cells, DC1) derived from adult peripheral blood is firstly performed. Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. By density 3.0×10 6 / ml, the cells were inoculated into T75 culture flasks, and 10% plasma was added to the GGT551 medium, placed at 37.0°C, saturated humidity, 5% CO 2 cultivated in the environment. After culturing for 3 hours, the suspended lymphocytes were washed away, and DMEM / F12 medium containing GM-CSF and IL-4 1000 IU / ml and 10% plasma was added. Adher...

Embodiment 2

[0039] Embodiment two (cell culture supernatant is NK cell and K562 cell co-culture supernatant)

[0040] Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. IL-2 (2000U / ml) and IL15 (2ng / ml) were added. Doubling the medium every two to three days, and supplementing the factors in equal amounts. Collected on the twelfth day. After the induction is completed, NK cells are treated by 1-3×10 6 / ml was inoculated into medium RPMI1640, IFNa (1000UI / ml) was added and 0.5-1.5×10 5 Inoculate K562 cells (can be replaced with K562-NK cells) at a density of / ml for mixed culture, collect the medium supernatant during 24-48 hours of activation, filter and freeze at -80 degrees or directly use it for the preparation of DC1 cells. Peripheral blood mononuclear ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a kit for activating sarcoma specific immunity response. The kit comprises an RPMI-1640 culture medium, a cell culture supernatant, a GM-CSF, an IL-4, an INF gamma and a sarcoma specific antigenic peptide combination. The sarcoma specific antigenic peptide combination includes MAGE-A1-A2 antigenic peptides, MAGE-A1-A3 antigenic peptides, MAGE-A3-A2 antigenic peptides, MAGE-A4-A2/3 antigenic peptides, PLAC1-A2 antigenic peptides, hTERT-A2 antigenic peptides, hTERT-A3 antigenic peptides, Survivin-A2 antigenic peptides and Survivin-A3 antigenic peptides. The kit can efficiently activate sarcoma specific immunity response in an active inducing/passive inducing combined mode.

Description

technical field [0001] The invention relates to a kit for enhancing anti-cancer immunity, in particular to a kit for activating sarcoma specific immune response. Background technique [0002] Malignant tumors derived from mesenchymal tissue (including connective tissue and muscle) are called "sarcomas" and mostly occur in the skin, subcutaneous tissue, periosteum, and both ends of long bones. Osteosarcoma is more common in young people and occurs at both ends of the long bones of the limbs, especially the lower end of the femur, the upper end of the tibia, and the upper end of the humerus. Osteosarcoma develops rapidly and has a short course of disease. It begins to grow in the cortex and gradually develops into the bone marrow cavity. Sometimes it breaks through the periosteum and invades the surrounding soft tissue, which can easily cause pathological fractures. Leiomyoma, lymphosarcoma, and synovium are common Sarcoma, etc., hematogenous metastasis can occur in the early...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0784C12N5/0783A61K39/00A61P35/00
Inventor 李伟叶圣勤汪鑫瞿苏
Owner SHANGHAI LONGYAO BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap